A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

Exclusion Criteria

• •Additional eye disease in the study eye that in the opinion of the Investigator could compromise assessment.
• •History of choroidal neovascularization in the study eye, or current choroidal neovascularization in the fellow eye requiring treatment.
• •Active Proliferative diabetic retinopathy (PDR) in the study eye or untreated active PDR in the fellow eye.
• •Ischemic maculopathy on fluorescein angiography.
• •Intraocular surgery or laser photocoagulation in the study eye within 90 day.
• •Use of intravitreal ranibizumab,or bevacizumab within 42 days (6 weeks), or aflibercept within 56 days (8 weeks) of dosing in the study eye.
• •Use of intraocular steroids in the study eye within 180 days of dosing.
• •Use of or expected need for intravitreal or intraocular treatment in the study eye during course of the study.
• •Use of any systemically administered anti-angiogenic agent within 6 months of dosing.
• •Evidence of vitreomacular traction as determined by the Investigator.
• •Uncontrolled intraocular pressure in the study eye despite treatment with glaucoma medication.
• •Within 6 months prior to the Screening Visit, use of medications known to be toxic to the retina, lens or optic nerve
• •Uncontrolled diabetes as indicated by glycated hemoglobin (HbA1c) \>12% at Screening.
• •Active ulcer disease or gastrointestinal bleeding by history within 6 months of screening or by exam at the time of screening.
• •Certain type of liver disease.
• •Participant who, in the Investigator's opinion, poses a significant suicide risk.
• •History or current evidence of any serious or clinically significant cardiac, gastrointestinal, renal, endocrine, neurologic, hematologic, infectious or other condition that is uncontrolled.
• •Corrected (QTc) interval \>450 milliseconds (msec) or QTc \>480 msec in participants with bundle branch block.
• •Use of certain medications that may interfere with the study medication or eye assessments (these will be identified by the study doctor).
• •Current enrollment, or recent participation in a study of investigational intervention or medical research.
• •Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study.
• •Any other reason the investigator deems the participant should not participate in the study.